Bristol Myers Squibb (BMY) Gross Profit (2016 - 2025)
Historic Gross Profit for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $8.8 billion.
- Bristol Myers Squibb's Gross Profit fell 165.64% to $8.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 billion, marking a year-over-year decrease of 605.62%. This contributed to the annual value of $34.3 billion for FY2024, which is 5.54% up from last year.
- Bristol Myers Squibb's Gross Profit amounted to $8.8 billion in Q3 2025, which was down 165.64% from $8.9 billion recorded in Q2 2025.
- In the past 5 years, Bristol Myers Squibb's Gross Profit registered a high of $9.6 billion during Q4 2021, and its lowest value of $7.5 billion during Q4 2024.
- Its 5-year average for Gross Profit is $8.8 billion, with a median of $8.9 billion in 2022.
- Its Gross Profit has fluctuated over the past 5 years, first soared by 2450.87% in 2021, then plummeted by 1376.55% in 2024.
- Bristol Myers Squibb's Gross Profit (Quarter) stood at $9.6 billion in 2021, then fell by 8.47% to $8.8 billion in 2022, then decreased by 0.92% to $8.7 billion in 2023, then fell by 13.77% to $7.5 billion in 2024, then rose by 16.69% to $8.8 billion in 2025.
- Its Gross Profit stands at $8.8 billion for Q3 2025, versus $8.9 billion for Q2 2025 and $8.2 billion for Q1 2025.